| dc.contributor.author | O'DRISCOLL, LORRAINE | en |
| dc.date.accessioned | 2017-01-18T15:53:43Z | |
| dc.date.available | 2017-01-18T15:53:43Z | |
| dc.date.issued | 2007 | en |
| dc.date.submitted | 2007 | en |
| dc.identifier.citation | O'Connor R, O'Leary M, Ballot J, Collins CD, Kinsella P, Mager DE, Arnold RD, O'Driscoll L, Larkin A, Kennedy S, Fennelly D, Clynes M, Crown J., A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer., Cancer Chemother Pharmacol., 59, 1, 2007, 79 - 87 | en |
| dc.identifier.other | Y | en |
| dc.description | PUBLISHED | en |
| dc.format.extent | 79 | en |
| dc.format.extent | 87 | en |
| dc.relation.ispartofseries | Cancer Chemother Pharmacol. | en |
| dc.relation.ispartofseries | 59 | en |
| dc.relation.ispartofseries | 1 | en |
| dc.rights | Y | en |
| dc.title | A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer. | en |
| dc.type | Journal Article | en |
| dc.type.supercollection | scholarly_publications | en |
| dc.type.supercollection | refereed_publications | en |
| dc.identifier.peoplefinderurl | http://people.tcd.ie/lodrisc | en |
| dc.identifier.rssinternalid | 54795 | en |
| dc.identifier.doi | 10.1007/s00280-006-0240-7 | en |
| dc.rights.ecaccessrights | openAccess | |
| dc.identifier.rssuri | http://www.ncbi.nlm.nih.gov/pubmed/16642371 | en |
| dc.identifier.orcid_id | 0000-0002-9860-8262 | en |
| dc.identifier.uri | http://hdl.handle.net/2262/78969 | |
